Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Topotecan and IV Carboplatin +/- Filgrastim in Extensive Stage SCLC
NCT00028925Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Nov 2001
- Primary completion
- Nov 2005
- Modality
- DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 2
01
Overview
Phase 2, open-label trial of topotecan, carboplatin and filgrastim in small cell lung cancer (SCLC) (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoints: Objective Response Rate up to 5 years and Tolerability up to 18 weeks. Started Nov 2001; status: completed.
02
Drugs
topotecancarboplatinfilgrastim
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00028925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00028925.